Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma
Abstract
The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDA has launched a new era of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC across all disease stages.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 20, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-4706
Entities
People
- Catherine E Willoughby
- Florian Castet
- Josep M. Llovet
- Philipp K. Haber
Organizations
- Carlos III Health Institute
- Catalan Institution for Research and Advanced Studies
- German Research Foundation
- Icahn School of Medicine at Mount Sinai
- United States Department of Defense
- University of Barcelona